Results 101 to 110 of about 1,335,871 (234)

Chinese Expert Consensus on Antiangiogenic Drugs for Advanced Non-small Cell 
Lung Cancer (2019 Edition)

Chinese Journal of Lung Cancer, 2019
Chinese Society of Clinical Oncology, Expert Committee on Vessel Targeted Therapy, Expert Committee on Non-small Cell Lung Cancer, Expert Group on Antiangiogenic Drugs for Non-small Cell Lung Cancer
doaj   +1 more source

Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer

New England Journal of Medicine, 2018
J. Soria, Y. Ohe, J. Vansteenkiste, T. Reungwetwattana, B. Chewaskulyong, K. Lee, A. Dechaphunkul, F. Imamura, N. Nogami, T. Kurata, I. Okamoto, Caicun Zhou, B. Cho, Ying Cheng, E. Cho, P. Voon, D. Planchard, Wu-Chou Su, J. Gray, S. Lee, R. Hodge, M. Marotti, Y. Rukazenkov, S. Ramalingam   +23 more
semanticscholar   +1 more source

SnapShot: Non-Small Cell Lung Cancer

Cancer Cell, 2012
Heist, Rebecca S., Engelman, Jeffrey A.
openaire   +2 more sources

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

The Lancet, 2017
A. Rittmeyer, F. Barlesi, D. Waterkamp, Keunchil Park, F. Ciardiello, J. von Pawel, S. Gadgeel, T. Hida, D. Kowalski, M. C. Dols, D. Cortinovis, J. Leach, J. Polikoff, C. Barrios, F. Kabbinavar, O. A. Frontera, Filippo de Marinis, H. Turna, Jong-Seok Lee, M. Ballinger, M. Kowanetz, P. He, Daniel S. Chen, A. Sandler, D. Gandara   +24 more
semanticscholar   +1 more source

Therapeutic vaccines in non-small cell lung cancer

ImmunoTargets and Therapy, 2013
Francisco Socola,1 Naomi Scherfenberg,2 Luis E Raez3 1Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Leonard M Miller School of Medicine, Miami, Florida, USA; 2University of Miami Leonard M Miller School of ...
Socola F, Scherfenberg N, Raez LE
doaj  

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

New England Journal of Medicine, 2016
M. Reck, D. Rodríguez-Abreu, A. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, Suman B. Rao, K. Hotta, M. Leiby, G. Lubiniecki, Shentu Yue, Reshma A. Rangwala, J. Brahmer   +17 more
semanticscholar   +1 more source

GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation

International Journal of Nanomedicine, 2014
Liang Cheng,1,* Fa-Zhen Huang,1,2,* Li-Fang Cheng,1 Ya-Qin Zhu,1 Qing Hu,1 Ling Li,1 Lin Wei1, Da-Wei Chen1 1Department of Pharmaceutics, College of Pharmaceutical Science, Soochow University, Suzhou, Jiangsu Province, 2Department of Pharmacy, Central ...
Cheng L, Huang FZ, Cheng LF, Zhu YQ, Hu Q, Li L, Wei L, Chen DW   +7 more
doaj  

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

New England Journal of Medicine, 2015
H. Borghaei, L. Paz-Ares, L. Horn, D. Spigel, M. Steins, N. Ready, L. Chow, E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhäufl, O. Arrieta, M. Burgio, J. Fayette, H. Léna, E. Poddubskaya, D. Gerber, S. Gettinger, C. Rudin, N. Rizvi, L. Crinò, G. Blumenschein, S. Antonia, C. Dorange, C. Harbison, Friedrich Graf Finckenstein, J. Brahmer   +27 more
semanticscholar   +1 more source

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

New England Journal of Medicine, 2015
J. Brahmer, K. Reckamp, P. Baas, L. Crinò, W. Eberhardt, E. Poddubskaya, S. Antonia, A. Płużański, E. Vokes, E. Holgado, D. Waterhouse, N. Ready, J. Gainor, O. Arén Frontera, L. Havel, M. Steins, M. Garassino, J. Aerts, M. Dómine, L. Paz-Ares, M. Reck, C. Baudelet, C. Harbison, B. Lestini, D. Spigel   +24 more
semanticscholar   +1 more source

Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments

, 2021

semanticscholar   +1 more source